LONDON, September 4, 2025 — Leads & Copy — Dr. Francesca Rapino of THERAtRAME SA has been named “Biotech CEO of the Year – Oncology Innovation & Breakthroughs” in Business Worldwide Magazine’s 2025 CEO Awards. The award recognizes her achievements in advancing oncology therapeutics through innovative approaches.
The 2025 CEO Awards celebrate leaders who are redefining industries and setting new standards in leadership, innovation, and impact. These awards spotlight the personalities who lead them.
THERAtRAME SA develops therapies that target hidden molecular vulnerabilities in cancer cells, focusing on multi-resistant and untreatable cancers. Dr. Rapino co-founded the company in 2022 and became CEO in 2025.
Under her leadership, THERAtRAME has raised nearly €8 million, advancing a pipeline of novel small-molecule drugs that inhibit tRNA modifications. These drugs combine targeted therapy with immunotherapy.
Dr. Rapino’s career includes a doctorate from Goethe University Hospital and oncology research. She is known for her ability to lead teams and align research innovation with business growth.
With a commitment to patient-centric innovation, Dr. Rapino is steering THERAtRAME towards first-in-human trials. “Our goal is to transform pioneering research into real-world solutions for patients with cancers that currently have no effective treatments,” said Dr. Rapino.
David Jones, Awards Department, E: david@bwmonline.com
Source: THERAtRAME SA
